Michael K. Murphy

Michael K. Murphy

Auto-generated profile, based on publicly available information

Michael K. Murphy

Department of Otolaryngology, State University of New York, Upstate Medical University, Syracuse, New York, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
KMKevin M. Motz
Kevin M. Motz
ILIoan A Lina
Ioan A Lina
ISIdris Samad
Idris Samad
MMMichael K. Murphy
Michael K. Murphy
MDMadhavi Duvvuri
Madhavi Duvvuri
AHAlexander T. Hillel
Alexander T. Hillel
Laryngotracheal stenosis (LTS) is pathologic fibrotic narrowing of the larynx and trachea characterized by hypermetabolic fibroblasts and CD4 + T cell–mediated inflammation. However, the role of CD4 + T cells in promoting LTS fibrosis is unknown. The mTOR signaling pathways have been shown to regulate the T cell phenotype. Here we investigated the influence of mTOR signaling in CD4 + T cells on LTS pathogenesis. In this study, human LTS specimens revealed a higher population of CD4 + T cells expressing the activated isoform of mTOR. In a murine LTS model, targeting mTOR with systemic sirolimus and a sirolimus-eluting airway stent reduced fibrosis and Th17 cells. Selective deletion of mTOR in CD4 + cells reduced Th17 cells and attenuated fibrosis, demonstrating CD4 + T cells’ pathologic role in LTS. Multispectral immunofluorescence of human LTS revealed increased Th17 cells. In vitro, Th17 cells increased collagen-1 production by LTS fibroblasts, which was prevented with sirolimus pretreatment of Th17 cells. Collectively, mTOR signaling drove pathologic CD4 + T cell phenotypes in LTS, and targeting mTOR with sirolimus was effective at treating LTS through inhibition of profibrotic Th17 cells. Finally, sirolimus may be delivered locally with a drug-eluting stent, transforming clinical therapy for LTS.

1 November 2017 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
KMKevin Motz
Kevin Motz
ISIdris Samad
Idris Samad
LYLinda X. Yin
Linda X. Yin
MMMichael K. Murphy
Michael K. Murphy
MDMadhavi Duvvuri
Madhavi Duvvuri
AHAlexander T. Hillel
Alexander T. Hillel
Laryngotracheal stenosis (LTS) is a critical narrowing of the glottis, subglottis, and/or trachea secondary to the development of pathologic fibrosis or scar. Laryngotracheal stenosis is most commonly a result of postintubation injury but can also be autoimmune related, radiation induced, or idiopathic.1,2 The multiple consequences of LTS include communication handicap and airway obstruction, a potentially life-threatening complication if not managed appropriately.1,3 The contemporary management of LTS is primarily surgical and includes serial dilation, tracheal or cricotracheal resection, laryngotracheoplasty, and/or permanent tracheostomy.4,5 Medical therapies available for the management of LTS are limited, reflecting a need for improved understanding of disease pathogenesis.

20 September 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
MMMichael K. Murphy
Michael K. Murphy
KMKevin M Motz
Kevin M Motz
DDDacheng Ding
Dacheng Ding
LYLinda Yin
Linda Yin
MDMadhavi Duvvuri
Madhavi Duvvuri
AHAlexander T. Hillel
Alexander T. Hillel